Sofosbuvir / velpatasvir (new indication: chronic hepatitis C; patients aged ≥ 3 - 6 years)

Subject:

• Active Substance: Sofosbuvir
• Name: Epclusa^®
• Therapeutic area: Chronic hepatitis C
• Pharmaceutical company: Gilead Sciences GmbH

Time table:

• Start: 15.02.2022
• Final decision by G-BA: 04.08.2022

Final decision:

• No additional benefit proved